EP3449944 - ORALLY ADMINISTERED NANOPARTICLES FOR GENE DELIVERY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 05.01.2024 Database last updated on 31.08.2024 | |
Former | Examination is in progress Status updated on 03.09.2021 | ||
Former | Request for examination was made Status updated on 01.02.2019 | ||
Former | The international publication has been made Status updated on 04.11.2017 | Most recent event Tooltip | 05.01.2024 | Application deemed to be withdrawn | published on 07.02.2024 [2024/06] | Applicant(s) | For all designated states KB Biomed Inc. Nano Bio Laboratory Chemical Bio Hall 50 Daehak-ro Chungju-si, Chungcheongbuk-do 27469 / KR | [2019/10] | Inventor(s) | 01 /
LEE, Yong-Kyu 107-603 12 Yeonsudongsan-ro Chungju-si Chungcheongbuk-do 27353 / KR | 02 /
LEE, Dong Yun 28-1701 113 Apgujeong-ro Gangnam-gu Seoul 06000 / KR | 03 /
KANG, Sung Hun 242 50 Daehak-ro Daesowon-myeon Chungju-si Chungcheongbuk-do 27469 / KR | 04 /
VISHNU, Revuri 109-10 Modan-gil Chungju-si Chungcheongbuk-do 27470 / KR | [2019/10] | Representative(s) | Schnappauf, Georg ZSP Patentanwälte PartG mbB Hansastraße 32 80686 München / DE | [2019/10] | Application number, filing date | 17789915.0 | 26.04.2017 | [2019/10] | WO2017KR04456 | Priority number, date | KR20160050955 | 26.04.2016 Original published format: KR 20160050955 | [2019/10] | Filing language | KO | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2017188731 | Date: | 02.11.2017 | Language: | KO | [2017/44] | Type: | A1 Application with search report | No.: | EP3449944 | Date: | 06.03.2019 | Language: | EN | [2019/10] | Search report(s) | International search report - published on: | KR | 02.11.2017 | (Supplementary) European search report - dispatched on: | EP | 03.12.2019 | Classification | IPC: | A61K47/50, A61K47/28, A61K47/12, A61K9/00, A61K48/00 | [2019/10] | CPC: |
A61P3/10 (EP,US);
A61K48/0041 (US);
A61K47/12 (EP,KR,US);
A61K47/28 (EP,KR,US);
A61K47/50 (EP,US);
A61K48/00 (EP,KR,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/10] | Title | German: | ORAL VERABREICHTE NANOPARTIKEL ZUR GENVERABREICHUNG UND PHARMAZEUTISCHE ZUSAMMENSETZUNG DAMIT | [2019/10] | English: | ORALLY ADMINISTERED NANOPARTICLES FOR GENE DELIVERY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | [2019/10] | French: | NANOPARTICULES À USAGE ORAL POUR L'ADMINISTRATION DE GÈNE ET COMPOSITION PHARMACEUTIQUE LES CONTENANT | [2019/10] | Entry into regional phase | 26.10.2018 | Translation filed | 26.10.2018 | National basic fee paid | 26.10.2018 | Search fee paid | 26.10.2018 | Designation fee(s) paid | 26.10.2018 | Examination fee paid | Examination procedure | deleted | Date on which the examining division has become responsible | 26.10.2018 | Examination requested [2019/10] | 19.06.2020 | Amendment by applicant (claims and/or description) | 02.09.2021 | Despatch of a communication from the examining division (Time limit: M04) | 30.12.2021 | Reply to a communication from the examining division | 26.04.2023 | Despatch of a communication from the examining division (Time limit: M04) | 07.09.2023 | Application deemed to be withdrawn, date of legal effect [2024/06] | 27.09.2023 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2024/06] | Fees paid | Renewal fee | 30.04.2019 | Renewal fee patent year 03 | 22.04.2020 | Renewal fee patent year 04 | 19.04.2021 | Renewal fee patent year 05 | 22.03.2022 | Renewal fee patent year 06 | 20.04.2023 | Renewal fee patent year 07 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XI]WO03017940 (ISIS PHARMACEUTICALS INC [US], et al) [X] 1,6-8,14,15 * [0010], [0012], [0020], [0028], [0031], [0044], [00131], [0133], [0014], [0050]-[0051];; claims 1-3,6, 9, 15-18 * [I] 5; | [A]US2013095187 (HAHN SEI KWANG [KR], et al) [A] 1-15* the whole document *; | [XI]WO2013185032 (HARVARD COLLEGE [US]) [X] 1-4,6-10,14,15 * [0070], [0073], [00222], ([0073]-[0075], [00190], [00298] point 47, [00298] point 57, [00133], [00298] point 2, [00172], [00298] point 9, ([00215], [0058], [00253];; claims 2, 9, 57 * [I] 5; | [X]KR20140091133 (KOREA ADVANCED INST SCI & TECH [KR]) [X] 1,8,10 * [0012], [0015]-[0016], [0020], [0030], [0043]-[0044], [0054]-[0058], [0035];; claims 1-5, 11-13 *; | [XP]WO2016070082 (UNIV UTAH RES FOUND [US], et al) [XP] 1-4,6-15 * [0002], [0055], [0057]-[0059], [0062], [0082], [0054], [0064], [0055], [0089], [0061], [0082], [0136], [0142], [0144], [0146], [0150], [0076], [0081], [0084], [0118], [0133], [0090]-[0091], [0096], [0087], [0112]-[0115];; claims 1-4, 10-11, 14-16 * | International search | [XY]KR20100122405 (KOREA INST SCI & TECH [KR]) [X] 1-11, 13-16 * See abstract, paragraphs [0022], [0032]: and claims 1-3, 13, 14. * [Y] 12, 17, 18; | [A]KR20110006188 (KOREA ELECTRONICS TELECOMM [KR]) [A] 1-18 * See the entire document. *; | [A]KR20140107995 (CHONG KUN DANG PHARM CORP [KR]) [A] 1-18 * See the entire document. *; | [A]KR20150021022 (ENGENE, INC.) [A] 1-18 * See the entire document. *; | [PX]KR20160112164 (UNIV KOREA NAT TRANSP IND ACAD COOP FOUND [KR], et al) [PX] 1-11, 13-16* See paragraph 100141; claims 1-9; and figure 1. *; | [Y] - JEAN, M. et al., "Chitosan-based Therapeutic Nanoparticles for Combination Gene Therapy and Gene Silencing of in vitro Cell Lines Relevant to Type 2 Diabetes", European Journal of Pharmaceutical Sciences, (20120000), vol. 45, no. 1, pages 138 - 149, XP028341138 [Y] 12, 17, 18 * See abstract and page 140. * DOI: http://dx.doi.org/10.1016/j.ejps.2011.10.029 |